Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Dimethylformamide | HCID 6228 | — |
| Reactant | Allyl bromide | HCID 7841 | — |
| Reactant | Cesium carbonate | HCID 10796 | — |
| Reactant | HCID 16457793 | HCID 16457793 | — |
| Solvent | Water | HCID 962 | — |
| Product | HCID 10112696 | HCID 10112696 | 66.1% |
Reaction Steps
1-[1-(4-Butyl-benzoyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one (197.2 mg, 0.522 mmol), allyl bromide (260 μL, 3.0 mmol) and cesium carbonate (excess) were added to dimethyl formamide (3 mL) and the suspension was stirred at 120° C. in a sealed tube for 72 hours. The reaction was allowed to cool to room temperature and diluted with water (9 mL) then extracted with ethyl ether (2×10 mL). The combined organic phase was dried over sodium sulfate and purified by column chromatography on silica gel using ethyl ether as the eluent. The product fractions were combined and concentrated to give an oily residue. The residue was triturated with ethyl ether and the white crystals that formed were collected by filtration. Vacuum drying yielded 1-allyl-3-[1-(4-butyl-benzoyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one (144 mg, 66%) as a white crystalline solid.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07244744B2 |
|---|
| Source dataset | uspto-grants-2007_07 |
|---|
| ORD ID | ord-44629bab4a564b5a82a557c6b3a634ef |
|---|
| Source note | uspto-grants-2007_07 |
|---|